HemoBioTech, Inc. Indicates ''HEMOTECH'' Commercial Development Strategy is Unaffected by Recent FDA/National Institutes of Health (NIH) Workshop on Blood Substitutes

DALLAS--(BUSINESS WIRE)--HemoBioTech (OTC Bulletin Board:HMBT.OB)(www.hemobiotech.com)- announced that its blood substitute, HemoTech, was not part of the National Institute of Health (NIH) safety analysis of the free hemoglobin-based oxygen carrying solutions that was recently published in JAMA, 2008;299(19); (http://jama.ama-assn.org/cgi/content/full/299.19.jrv80007v1). This meta-analysis reported a 30 percent higher risk of death overall for patients who received transfusions using the first-generation blood substitute products developed by five different companies; Baxter, Hemosol, Biopure, Northfield and Sangart. According to the study, the risk of heart attack nearly tripled in the groups receiving these blood substitutes.

Back to news